U.S. markets closed

60 Degrees Pharmaceuticals, Inc. (SXTP)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.2919+0.0193 (+7.08%)
At close: 04:00PM EST
0.2900 -0.00 (-0.65%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.2726
Bid0.2910 x 800
Ask0.2920 x 3000
Day's Range0.2700 - 0.2950
52 Week Range0.2580 - 8.6500
Avg. Volume825,661
Market Cap3.232M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.5900
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.20
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SXTP

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • 60 Degrees Pharmaceuticals, Inc
    Daily – Vickers Top Buyers & Sellers for 02/05/2024The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
    Fair Value
    Economic Moat
    26 days agoArgus Research
View more
  • GlobeNewswire

    60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

    Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitalsTafenoquine’s presumed mode of action against C. auris is differentiated from standard of care treatmentMonash University will conduct the studies beginning in second quarter of 2024 WASHINGTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company,” “60P” or “60 Degrees Pharmaceuticals”) (NASDAQ: SXTP; SXTPW), specialists in developing and marketing medicines for infectiou

  • GlobeNewswire

    60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

    To lead U.S. commercial relaunch of ARAKODA® (tafenoquine) for malaria preventionWill support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON, Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today it has appointed Kristen Landon to the newly created role of Chief Commercial Of

  • PR Newswire

    WallachBeth Capital Announce Closing of 60 Degrees Pharmaceuticals $2.4 Million Public Offering

    WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc., ("60P," NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines for infectious diseases, has completed its previously announced Public Offering of 5,260,901 units (the "Units") at a price to the public of $0.385 per Unit and 999,076 pre‑funded units (the "Pre‑Funded Units") at a price to the public of $0.375 per Pre‑Funded Unit